The senator of the United States says that diabetes and drugs have changed his life, that’s why why

A senator from the United States said that a GLP-1 drug has changed his life-and now asks for ample access to anti-obesity drugs.

In a New York Times, on April 8, Senator John Sfretman, D-Pa., He wrote about his experience with Mounjaro (Tirzepatide).

The injectable prescription medicine is mainly used to treat type 2 diabetes.

Do Ozempic’s health benefits continue to grow, but are the risks worth it?

The drug was prescribed in Sfreterman in July 2025.

“As a Survivor of the strokeI was interested in the studies showing (Mounjaro) could significantly reduce the risk of main heart events, “wrote the senator.

Senator John Sfretman, D-P., walks towards the Chamber of Capitol Hill in Washington, DC, on March 14, 2025. In an editorial on April 8, Pennsylvania senator wrote about his experience with Mounjaro (Tirzepatide). (Reuters)

“Even if I started taking it for mine Heart healthI was struck by how much he made me feel throughout the line. He had a significant impact on my general health, “he continued.

“Pain, pain and rigidity have vanished. Physically, a younger decade, as well as a clearer and more optimistic head than I had been over the years. As for the side effects, I have also lost about 20 kilos.”

Genetic cholesterol eliminated by a new drug, reducing the risk of heart attack, the study discovers

In addition to reducing blood sugar, GLP-1 drugs have also been connected to a series of other benefits, including better heart health, neurological function and metabolic health, as reported by Fox News Digital.

Eli Lilly, manufacturer of Mounjaro, also offers another version of the drug called Zepbound, which is the same drug approved for weight loss, chronic weight management e Night apnea.

Other drugs GLP-1 include Ozepic, Wegovy, Vicloza, Saxenda, all made by New Nordisk.

Senator Sfretman is depicted in the White House on January 29, 2025. “As a survivor of the strokes, I was interested in the studies that show (Mounjaro) could significantly reduce the risk of important heart events,” wrote the senator in an editorial in April. (Reuters)

Sfretman observed that GLP-1 drugs had beneficial effects on cholesterol, heart rate and cardiac inflammation.

“Some recent studies suggest that they may also help brake Alcohol dependence And support the cognitive function, potentially slowing down or preventing conditions such as Parkinson’s and Alzheimer’s, “he wrote in the time.

“Physically, I feel like a younger decade, as well as clearer and more optimistic than I had been over the years.”

In the operator, Sfteman asked for an extensive access to These drugswhich can cost up to $ 1,000 on your pocket if not covered by the insurance.

“Currently, medicare covers these drugs only in specific circumstances, such as for diabetes or a high heart risk,” he wrote. “And the Medicoid coverage is even more limited.”

Sfretman added that he was not compensated for sharing his experience.

Ozempico’s “microdosage” is the new tendency of weight loss

“I am just a boy who has benefited from these drugs and wants to make sure that anyone can benefit from them can also have access to them,” he wrote.

While Sfretman shares HHS sec. Robert F. Kennedy Jr. on the priority of nutrition and healthy life, the opinions of healthy life said that the drugs are necessary for some.

Eli Lilly, manufacturer of Mounjaro, also offers another version of the drug called Zepbound, which is the same drug approved for weight loss, chronic weight management and night apnea. (Istock)

“I fully agree that the diet e Matter of lifestyle – Very. But the diet alone is not enough, “he wrote.

“For the millions of Americans who fight with serious health problems, drugs can be a first crucial step to resume sufficient control of their health to start making significant changes in lifestyle”.

Doctors discuss benefits and access

Dr. Marc Siegel, clinical professor of Medicine at the Nyu Langone Health and the Senior Medical Analyst of Fox News, observed that the semaglutids, including Ozempic and Wegovy, are “very important drugs” for Type 2 diabetesWith growing use for obesity.

“Although these drugs seem to have benefits for the cardiac and lipid profile – and also the brain and the decreasing risk of dementia – studies are underway and more data are still needed,” he told Fox News Digital.

The first approach to obesity It is changes in lifestyle, including exercise, improved diet and optimal sleep, said Siegel.

“Having said that, these weight loss drugs (including zepbound) are also good tools when lifestyle is not enough,” he observed.

Mounjaro was prescribed for potential benefits for heart health. (Getty Images)

“They help prevent in line diseases such as heart disease, stroke, hypertension and night apnea, which tend to come from obesity.”

He added: “Overall, we are saving the money of the health system, so I would like to see medicine and medicoid approve of them for diabetes and weight loss. “

Click here to subscribe to our health newsletter

Dr. Brett Osborn, Florida’s neurologist and longevity expert, said he prescribed Glp-1 to his patients since 2019.

“Mounjaro and his cousins ​​are not just weight loss tools: they are metabolic restoration buttons,” he told Fox News Digital.

In addition to reducing blood sugar, GLP-1 drugs have also been connected to a series of other benefits, including better heart health, neurological function and metabolic health. (Istock)

“People with metabolic syndrome do not need lessons on cabbage and the importance of exercise. They need help.”

Osborn agreed that the lifestyle is essential, but it is “rarely enough”.

“The GLP-1s lengthen the patients by rolling the ball,” he said. “And when this happens, health habits are formed. The diet improves. The movement improves. People begin to feel the benefits of healthy life.”

For other health articles, visit www.foxnews.com/health

Osborn observed that these drugs are not cosmetics, but therapeutic.

“I saw what they can do in first person: reductions in body fat, inflammation, glucose, triglycerides and insulin resistance – and with those, significant reductions in the incidence of stroke and heart attack.”

“I think this is a signal aimed exactly at Big Pharma.”

The administration of President Donald Trump recently announced that medicating and Medicaid would not have covered the drugs, as the centers to medicate and Medicaid Services said on Friday.

Osborn said that the transition to block the coverage probably has no efficacy.

“Trump knows these drugs work,” said Osborn. “I think this is a signal addressed exactly to the Big Pharma: ‘Lower the price, or medicate, the largest buyer of the block, is out.'”

Click here to get the Fox News App

“This is not a dismissal – it’s a lever,” said Osborn.

“President Trump will probably play until the” price will be right “, without the power of Big Pharma, improving the health of the Americans in conjunction”.